Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 1, 2013

Novartis, Oxford BioMedica Ink Production Agreement for Lentiviral Gene Therapy

  • Oxford BioMedica has agreed to produce clinical trial material using its LentiVector® gene delivery technology for Novartis’ use as part of its CTL019 leukemia program, a collaboration with scientists at the University of Pennsylvania, the company announced today.

    Through this production agreement, Oxford BioMedica will be responsible for manufacturing a lentiviral vector-encoding CTL019 technology, which Novartis et al., will use to transduce patients’ T-cells ex vivo before they are reinfused. In its announcement, Oxford BioMedica notes that CTL019 targets the protein CD19, which is associated with a number of B-cell malignancies, including chronic lymphocytic leukemia, B-cell acute lymphocytic leukemia, and diffuse large B-cell lymphoma.

    Under the terms of the agreement, Oxford BioMedica stands to make anywhere from £2.5 million ($3.9 million) to £4 million ($6.2 million) during the first year of collaboration, the firm added.

    According to Edison Research Investment, Oxford BioMedica’s deal with Novartis is expected to raise the gene-based therapy firm’s valuation from £58.5 million ($91 million) to £60.1 million ($93.6 million) in that same timeframe.

    Edison calls the transaction “an attractive deal of Oxford BioMedica,” adding that it could eventually lead to a longer-term supply agreement.

    In a statement, Oxford BioMedica CEO John Dawson said that Novartis’ “strategic investment in our specialist manufacturing capabilities is a pivotal step towards building a financially self-sustaining business,” adding that “this collaboration is an example of how we can commercialize our expertise.”



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »